841-5 Attenuation of human atherosclerotic plaque inflammation by PPAR-γ agonist and NF-κB inhibitor  by Mazurek, Tomasz et al.
506A ABSTRACTS - Vascular Disease, Hypertension, and Prevention JACC  March 3, 2004
Va
sc
ul
ar
 D
is
ea
se
, H
yp
er
te
ns
io
n,
 a
nd
 P
re
ve
nt
io
n
Material & Methods Ten histologic sections of human coronary plaque rupture were
contrasted with ten cases of stable fibrocalcific plaques for the presence of peri-adventi-
tial fat macrophages (Kp-1 positive cells). Quantitative morphometry was performed.
Results. The ten plaque rupture cases had a markedly greater macrophage infiltration
as evidenced by number/mm2 peri-adventitial fat. Moreover, the highest density in fibro-
calcific cases (56/mm2) was lower than the lowest density in cases of plaque rupture
(171/mm2). As expected, plaque rupture sections showed typical features of thin cap
fibroatheroma with large lipid cores and high density of plaque macrophages that were
accompanied by a significant macrophage infiltrate in the adventitia and peri-adventitial
fat. S100 and Toluidine blue staining ruled out the possibility that these cells might repre-
sent dendritic cells or mast cells, respectively.
Conclusion. This study shows the presence of active macrophages in the peri-adventi-
tial fat of human coronary arteries. These cells were present in much greater quantity in
the setting of plaque rupture as opposed to burnt-out fibrocalcific plaques. There
appeared to be no significant difference in macrophage density between adventitia and
peri-adventitial fat. Peri-adventitial fat inflammation might play a significant pathogenic
role in atherosclerosis progression and complications.
11:00 a.m.
841-3 Apolipoprotein A1 Mimetic Peptide Reduces 
Accelerated Atherosclerosis in a Vein Graft Bypass 
Model in ApoE (-/-) Mice
Xiaojun Li, Kuang-Yuh Chyu, Jose R. Faria Neto, Juliana Yano, Paul C. Dimayuga, Bojan 
Cercek, Prediman K. Shah, Cedars-Sinai Medical Center, Los Angeles, CA
BACKGROUND: ApoA-1 mimetic peptide (DWFKAFYDKVAEKFKEAF or D4F) reduces
diet-induced aortic atherosclerosis. Whether D4F is effective in reducing accelerated ath-
erosclerosis in vein graft is unknown. We studied the effect of intraperitoneal (IP) admin-
istration of D4F on accelerated atherosclerosis in a murine vein graft bypass model.
METHODS: Right carotid artery of hypercholesterolemic apoE (-/-) mice were grafted
with a segment of IVC from donor mice at 16 weeks of age. Treatment group (n=10)
received IP injection of 50 mcg D4F peptide daily for 4 weeks after surgery whereas con-
trol group (n=7) received saline injections. The grafts, heart and aorta were harvested
and sectioned for morphometric and immunohistochemical analysis and plasma col-
lected for cholesterol and D4F levels and lipoprotein fractionation analysis.
RESULTS: D4F treatment significantly reduced plaque size in the vein graft but not in the
aortic sinus or aorta. D4F also reduced lipid content in the vein graft but not in the aortic
sinus plaques (Table). There were no difference in cholesterol levels or lipoprotein frac-
tionation or plaque phenotypes in the vein graft or aortic sinus plaques between the
groups.
CONCLUSION: Four week treatment of Apo A-1 mimetic peptide reduces accelerated
atherosclerosis in vein graft but has no effect on native spontaneous atherosclerosis in
apoE (-/-) mice. 
*: p<0.05, by t-test
11:15 a.m.
841-4 Bach1 Is a Key-Repressor of Heme Oxygenase-1 and 
Regulates Cell Proliferation
Shinji Omura, Jiying Sun, Hiroshi Suzuki, Kazuhiko Igarashi, Hiroshima University, 
Hiroshima-City, Japan
Background: Heme oxygenase-1 (HO-1) protects cells from various insults including
oxidative stress and its transcriptional induction by various stresses provides an impor-
tant cellular adaptive defense mechanism. Recently we found that Bach1 is a physiologi-
cal repressor of HO-1 (EMBO J., 2002). Though some investigators reported that HO-1
protects against vascular proliferation, the role for Bach1 in cell growth is poorly under-
stood. The aim of this study is to elucidate the association between Bach1 and HO-1
expression and to examine the effect of bach1 ablation on cell proliferation.
Methods: We have developed bach1 knockout (KO) mice and isolated aortic smooth
muscle cells (SMC), macrophages, and embryonic fibroblasts (EF). Using RT-PCR
method, western blotting and immunofluorescence staining, we analyzed the expression
of HO-1 comparing them with that in wild type (WT) cells. Using retrovirus system we
studied whether re-introduction of bach1 represses the expression HO-1 in KO cells or
not. We also investigated effect of bach1 ablation on cell proliferation using BrdU labeling
assay both atmospheric levels (20%), which is oxidative condition for EF, and physiologi-
cal levels of oxygen (3%). We detected the senescent cells with senescence β-galactosi-
dase staining.
Results: Expression of HO-1 was increased in KO SMC, macrophages and EF as com-
pared with WT cells (4.2-fold and p<0.01; 3.6-fold and p<0.05; 3.6-fold and p<0.01,
respectively). While HO-1 expression was induced in WT cells when stimulated with Cd
or hemin, no further induction was observed in the KO cells. Thus, HO-1 is fully activated
in the absence of bach1 function. Expression of HO-1 was clearly inhibited in KO cells
upon bach1 gene delivery. In 20% O2, proliferation of KO SMC and EF significantly
decreased in both cell counting and in BrdU labeling assays. In 3% O2, KO EF prolifer-
ated as well as WT cells. When cultured in 20% O2, KO EF underwent senescence more
frequently than WT cells.
Conclusion: Inactivation of bach1 leads to increased expression of HO-1 and anti-prolif-
erative effect. Bach1 is an important molecule for the response of oxidative stress. Bach1
may represent a novel molecular target in anti-atherosclerotic therapy.
11:30 a.m.
841-5 Attenuation of Human Atherosclerotic Plaque 
Inflammation by PPAR-γ Agonist and NF-κB Inhibitor
Tomasz Mazurek, LiFeng Zhang, Andrew Zalewski, Mark Kahn, Anthony Carabasi, Paul 
J. Dimusio, Rhoda Leichter, Ping Zhang, Anthony G. Johnson, Yi Shi, Thomas Jefferson 
University, Philadelphia, PA
Background: Although inflammation plays an important role in formation, progression
and instability of atherosclerotic plaque, its inflammatory properties have not been fully
examined. Since the reduction of plaque inflammation may improve clinical outcomes in
high-risk individuals, we examined inflammatory properties of human atherosclerotic
plaque, and evaluate anti-inflammatory potential of PPAR-γ Agonist and NF-κB Inhibitor
in an ex-vivo organ culture system utilizing advanced human atherosclerotic plaque for
drug discovery.
Methods: Human atherosclerotic plaques (CaP; n=20) were obtained during carotid
endaterectomy. Unaffected vessels (radial arteries and saphenous veins: NV; n=8) were
harvested during elective CABG surgery. Tissue expression of inflammatory mediators
was analyzed by real-time RT-PCR (mRNA), and ELISA at baseline, after 2 and 24 hours
incubation in the absence or presence of PPAR- γ agonist (rosiglitazone, 20 µM, n=14) or
NK-κB inhibitor (MG-132, 100 µM, n=9).
Results: At the baseline, CaP exhibited higher expression of IL-1β (7.8±2.1 vs. 1.9±0.4;
p<0.01), TNF-α (0.9±0.1 vs. 0.3±0.1; p<0.01) and MCP-1 (0.9±0.1 vs. 0.3±0.1; p<0.01)
on mRNA level, as compared to NV (respectively). After stimulation, rosiglitazone
reduced TNF-α expression (4.4±0.9 vs. 2.3±0.4; p<0.05), whereas NFkB inhibitor attenu-
ated TNFα (4.6±0.9 vs. 0.7±0.2; p<0.05), IL-6 (91.2±38 vs. 2.5±0.4; p<0.05), IL-8
(17.1±1.3 vs. 1.7±0.7; p<0.001), and MCP-1 (54.0±13.4 vs. 3.0±0.5; p<0.05) expression
on protein and mRNA levels (not shown).
Conclusions: 1. Atherosclerotic plaque releases higher levels of inflammatory media-
tors, as compared to normal vessel; 2. Inflammatory properties of atherosclerotic plaque
are modifiable, that provides experimental platform for novel drug discovery in athero-
sclerosis; 3. Further evaluation of therapy targeting specific inflammatory pathways is
necessary.
11:45 a.m.
841-6 Interleukin-18 and Interleukin-18 Binding Protein in 
Patients With Acute Coronary Syndromes
Craig R. Narins, David A. Lin, Zheng-Gen Jin, Bradford C. Berk, University of Rochester, 
Rochester, NY
Background: Interleukin-18 (IL-18) is a pro-inflammatory cytokine produced by macroph-
ages that induces interferon-γ production in T-cells, and acts with IL-12 to upregulate T-
helper cell activity. In animal models IL-18 is a potent promoter of both atherogenesis and
plaque instability, and among patients with coronary disease serum IL-18 is a predictor of
subsequent cardiovascular death. IL-18 binding protein (IL-18BP) is a recently identified
circulating high-affinity antagonist that binds to and neutralizes IL-18. We sought deter-
mine (1) The strength of the relationship between serum IL-18 concentration and clinical
coronary events, and (2) the nature of the relationship between IL-18 and IL-18BP
among patients with coronary artery disease.
Methods: Serum concentrations of IL-18, IL-18BP and other inflammatory mediators (IL-
5, IL-8, IL-12, IL-13, anti-HSP60, GM-CSF, TNF, MCP-1, IFN-γ) were measured immedi-
ately prior to coronary angioplasty in 79 patients. Patients were grouped as acute coro-
nary syndrome positive (ACS+) or negative (ACS-) based on presence or absence of
elevated troponin I levels.
Results: No significant differences existed between ACS+ and ACS- patients with respect
to clinical variables (including age, gender, prior MI, smoking, cholesterol, hypertension,
diabetes). The IL-18 concentration was significantly greater among ACS+ vs. ACS-
patients (452 ± 384 vs. 301 ± 172 pg/ml, p=0.017). There was, however, no significant
difference between the groups with respect to IL-18BP levels, as reflected by an elevated
ratio of IL-18 / IL-18BP among the ACS+ compared to ACS- patients (150 ± 145 vs. 89 ±
67, p=0.011). Of all mediators examined, only IL-18 was significantly associated with the
presence of recent ACS.
Conclusions: IL-18 emerged as the most potent correlate of recent plaque instability
among the mediators and clinical variables examined. The elevated serum IL-18 concen-
trations present in the ACS+ patients were not “opposed” by a concomitant rise in IL-
18BP levels. These findings support a clinical association between IL-18 and plaque
instability, and support further study of IL-18BP as a potential means to modulate the
pro-inflammatory effects of IL-18.
Group Cholesterol
(mg/dl)
vein graft
plaque 
size (mm2)
lipid content 
in vein graft
(%)
aortic 
sinus 
plaque 
size
(mm2)
Lipid 
content in 
aortic sinus
(%)
D-4F conc. 
(pmole/ml)
Control 1424±467 0.96±2.03 12.4±6.5 0.39±0.12 17.5±6.2 ND
D4F 1273±294 0.55±0.37* 6.4±3.8* 0.50±0.09 18.0±6.6 3767±1183
